Introduction {#section1-2036361318787626}
============

Sarcomas are a rare group of malignant tumors that arise from mesenchymal tissues. They compromise less than 1% of all cancers in adults with 15,600 new cases diagnosed in the United States in 2016.^[@bibr1-2036361318787626]^ Histopathology of sarcomas is highly heterogeneous with over 200 distinct histologic subtypes described.^[@bibr1-2036361318787626],[@bibr2-2036361318787626]^ The most prevalent subtype is gastrointestinal stromal tumor (GIST) followed by fibrosarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor (MPNST).^[@bibr2-2036361318787626],[@bibr3-2036361318787626]^ Most sarcomas are sporadic; however, there are key environmental causative factors including history of ionizing radiation, exposure to vinyl chloride, and human herpes virus 8 (HHV-8).^[@bibr4-2036361318787626]^ Known genetic syndromes associated with a predisposition to sarcoma include Li-Fraumeni syndrome, retinoblastoma, neurofibromatosis type 1, Carney's triad, and familial adenomatous polyposis syndrome. In addition, the association of GIST with multiple other malignancies and desmoid tumor is well documented.^[@bibr5-2036361318787626],[@bibr6-2036361318787626]^

On the contrary, sarcoidosis is a multisystem disease of unknown etiology. The incidence of sarcoidosis has been estimated at approximately 1--35 cases per 100,000 with the highest rates among Northern Europe and African American populations.^[@bibr7-2036361318787626]^ Any organ may be involved, but the most common presenting sites are the lung and lymphatic system.^[@bibr8-2036361318787626]^ It is thought that sarcoidosis occurs after antigen exposure induces recruitment, activation, and aggregation of macrophages with granulomatous inflammation. Subsequently, the disease follows one of two pathways: resolution or progression leading to fibrosis. The susceptibility and spectrum of manifestations is driven by genetic susceptibility; strong association has been found for MHC-2 alleles HLA DRB1\*3 for remitting disease and HLA DRB1\*14 and 15 for a chronic course. Co-stimulator molecules and cytokine polymorphisms have also been linked with different clinical manifestations.^[@bibr7-2036361318787626],[@bibr9-2036361318787626]^

Several case reports and descriptive studies have suggested an increased risk of malignancy in patients with sarcoidosis. Concomitant occurrence of cancer is found in 1.2%--2.5% of patients with sarcoidosis.^[@bibr10-2036361318787626]^ In 2015, a meta-analysis of 16 studies (10 cohorts and 6 case--control studies) involving a total of 27,268 patients and 1952 cancer cases reported a relative risk (RR) of 1.19 (confidence interval (CI): 1.07--1.32) for the development of any invasive cancer. The association was stronger for skin (RR: 2.00) and hematologic malignancies (RR: 1.92) during the first 10 years after diagnosis.^[@bibr11-2036361318787626]^ The implications of sarcoidosis development following the diagnosis of malignancy are also reported. A descriptive study found 64 patients (from 1980 to 2011) with a cancer diagnosis who subsequently developed sarcoidosis. In this cohort, the associated malignancies were breast, lymphoma, lung, and testicular cancer. Results showed that among patients developing sarcoidosis, 53% developed recurrence of the primary cancer and 67% developed a secondary malignancy. These findings showed that sarcoidosis is often discovered before or at diagnosis of cancer. Still, it is associated with recurrence or second malignancy in a significant proportion of patients.^[@bibr12-2036361318787626]^

The association of sarcoma and sarcoidosis is quite rare in the literature; there are no published series, and the implications of this coexistence are not known. We found single patient case reports (six since 1978) describing an association of sarcoidosis with two cases of osteosarcoma and one case each of GIST, gastric leiomyosarcoma, angiosarcoma, and one reported as low-grade sarcoma.^[@bibr13-2036361318787626][@bibr14-2036361318787626][@bibr15-2036361318787626][@bibr16-2036361318787626][@bibr17-2036361318787626]--[@bibr18-2036361318787626]^ Herein, we describe the concomitant occurrence of sarcoidosis in eight patients diagnosed with sarcoma at a comprehensive sarcoma center since 2007. This case series constitutes the largest of its kind, suggests a nonrandom association of these two conditions, and will directly impact clinical practice by raising awareness of a potential mimic of metastasis.

Materials and methods {#section2-2036361318787626}
=====================

Patients and pathology tissues {#section3-2036361318787626}
------------------------------

This case series includes eight patients with concomitant soft-tissue sarcoma and sarcoidosis. After initial protocol review by University of Miami Institutional Review Board, approval to proceed was given and further review waved according to the size and retrospective nature of the study. The data supporting the findings of this study are available from the corresponding author, A.P.E., on request.

Clinical characteristics and pathology data were retrieved from patient records at The University of Miami, Sylvester Comprehensive Cancer Center. Five of the eight tissue samples were available and evaluated by an experienced sarcoma pathologist who confirmed sarcoidosis and sarcoma histology. Unavailable samples correspond to the cases were sarcoidosis was diagnosed several years prior to sarcoma. Demographic and clinical information including presentation, treatment, histology, and outcome-related variables were tabulated for analysis.

Statistical analyses {#section4-2036361318787626}
--------------------

The standardized incidence ratio (SIR) was used to determine whether the association between sarcoma and sarcoidosis was due to chance. This ratio is calculated by the number of events observed divided by the number of events expected. The overall population used was the hospital catchment area (6.5 million people) and the state of Florida (20.2 million people). SIR has shown to be a useful tool to analyze incidence data prior to large, expensive, population-based studies.^[@bibr19-2036361318787626]^ We calculated 95% CIs of SIR using the Vandenbroucke^[@bibr20-2036361318787626]^ method. Descriptive statistics were used to analyze demographic, tumor, and treatment data.

Results {#section5-2036361318787626}
=======

Clinical characteristics {#section6-2036361318787626}
------------------------

Eight patients with diagnosis of soft-tissue sarcoma and sarcoidosis seen between 2007 and 2016 were analyzed in this case series. [Table 1](#table1-2036361318787626){ref-type="table"} shows the clinical characteristics of these patients, which includes six females (75%) and two males (25%). Ethnicity was Caucasian in five patients, two African American, and one Hispanic. Pain was the most common presenting symptom; three cases presented as painless mass, two as abdominal pain, two cases as incidental finding, there was no data on presentation for one patient.

###### 

Patient and tumor properties, summary of eight patients who developed soft-tissue sarcomas and sarcoidosis.

![](10.1177_2036361318787626-table1)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case no.                         Age                                                                    Sex   Ethnicity             Histology of sarcoma and additional tumors             Histologic grade                                                   Tumor markers          Staging at presentation   Treatments used                   Onset of sarcoidosis        Presentation of sarcoidosis   Length of follow-up (months)   Date of progression                       Patient status
  -------------------------------- ---------------------------------------------------------------------- ----- --------------------- ------------------------------------------------------ ------------------------------------------------------------------ ---------------------- ------------------------- --------------------------------- --------------------------- ----------------------------- ------------------------------ ----------------------------------------- ----------------
  1                                40                                                                     F     Caucasian             Unclassified spindled and epithelioid cell sarcoma     Grade 3                                                            CD10, TFE-3, Inhibin   Stage IIA (T1aN0M0G3)     Surgical resection radiation      1.5 years after diagnosis   Chest X-ray surveillance      39                             No progression                            NED

  Tenosynovial giant cell tumor    NA                                                                     ND    NA                    Surgical resection                                                                                                                                                                                                                                                                                                                              

  2                                57                                                                     F     Hispanic              Gastrointestinal stromal tumor                         High risk^[a](#table-fn2-2036361318787626){ref-type="table-fn"}^   Kit exon 11 mutation   Stage IV (T4N1M1)         Imatinib\                         1 year after diagnosis      Chest X-ray surveillance      65                             1 year after diagnosis                    AWD
                                                                                                                                                                                                                                                                                                                 Sunitinib                                                                                                                                                            

  3                                47                                                                     M     Caucasian             Gastrointestinal stromal tumor                         ND                                                                 Kit exon 11 mutation   Stage I                   Imatinib                          Before diagnosis            ND                            73                             No progression                            NED

  4                                63                                                                     F     Caucasian             Uterine leiomyosarcoma                                 ND                                                                 ND                     Stage IV (T2bN1M1)        Gemcitabine\                      Before diagnosis            ND                            23                             At best mixed response during treatment   D
                                                                                                                                                                                                                                                                                                                 Docetaxel\                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                 Doxorubicin\                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                 Adriamycin\                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                 Ifosfamide\                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                 NOTCH inhibitor\                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                 Palliative radiation                                                                                                                                                 

  5                                66                                                                     F     African American      Myxofibrosarcoma                                       Grade 3                                                            Negative               Stage IIB (T2bN0M0)       Surgical resection doxorubicin\   7 months after diagnosis    CT chest surveillance         15                             2 months after diagnosis                  D
                                                                                                                                                                                                                                                                                                                 Cyclophospham ide radiation                                                                                                                                          

  6                                76                                                                     F     African American      Invasive moderately differentiated mammary carcinoma   Grade 2                                                            ER/PR                  Stage I                   None                              Before diagnosis            ND                            58                             ND                                        ND

  Gastrointestinal stromal tumor   Very low risk^[a](#table-fn2-2036361318787626){ref-type="table-fn"}^   ND    Stage I A (T1bN0M0)   Surgical resection imatinib                                                                                                                                                                                                                                                                                                                     

  Metanephric adenoma              NA                                                                     ND    NA                    Surgical resection                                                                                                                                                                                                                                                                                                                              

  7                                55                                                                     M     Caucasian             Gastrointestinal stromal tumor                         High risk^[a](#table-fn2-2036361318787626){ref-type="table-fn"}^   PDGFR exon 12          Stage IIIB (T4N0M0)       Surgical resection Imatinib       At the time of diagnosis    CTA incidental finding        9                              No progression                            NED

  8                                68                                                                     F     Caucasian             Gastrointestinal stromal tumor                         High risk^[a](#table-fn2-2036361318787626){ref-type="table-fn"}^   PDGFR exon 18          Stage IIIB (T4N0M0)       Imatinib\                         2.5 years after diagnosis   Surgical pathology            56                             2.5 years after diagnosis                 AWD
                                                                                                                                                                                                                                                                                                                 Sunitinib                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: no applicable; ND: no data; NED: no evidence of disease; AWD: alive with disease; D: deceased; CT: computed tomography; CTA: computed tomography angiography; NIH: National Institutes of Health; GIST: gastrointestinal stromal tumors.

NIH 2002 consensus approach to GIST risk stratification.^[@bibr21-2036361318787626]^

Sarcoma histology {#section7-2036361318787626}
-----------------

Sarcoma subtypes included GIST in five patients with one patient also diagnosed with concurrent breast cancer and a metanephric adenoma. Mutation analysis of GIST cases revealed mutation of KIT exon 11 in two patients, PDGFR exon 12 in one patient, PDGFR exon 18 in one patient, and one patient had no mutational analysis done. Another case was an unclassified spindled and epithelioid cell sarcoma that coexisted with tenosynovial giant cell tumor. Finally, there was one patient with uterine leiomyosarcoma, and one diagnosed with myxofibrosarcoma. Two patients were diagnosed at stage I, two at stage II, two at stage III, and two at stage IV.

Patient presentations {#section8-2036361318787626}
---------------------

In three patients, sarcoidosis was diagnosed before the onset sarcoma, four patients were diagnosed with sarcoidosis after the sarcoma diagnosis, and one patient was diagnosed with sarcoidosis at presentation of sarcoma with coexistent metastatic disease and sarcoidosis in the lungs. When sarcoidosis was diagnosed after sarcoma, the average time for diagnosis was 16 months (range: 7 months to 2.5 years). Sarcoidosis was diagnosed after abnormal chest imaging for surveillance in three patients. In one patient, sarcoidosis was found incidentally after undergoing imaging for suspected pulmonary embolism, and in one patient sarcoidosis was found by pathology in all abdominal lymph nodes and the spleen resected at surgery for recurrence. Data regarding presentation were unavailable in the three patients with history of sarcoidosis prior to the diagnosis of cancer. Seven cases were of pulmonary sarcoidosis and one was found in abdominal lymph nodes and spleen. [Figure 1](#fig1-2036361318787626){ref-type="fig"} shows the imaging and pathology findings of patient number 2. The surveillance positron emission tomography/computed tomography (PET/CT) scan was initially thought to represent metastasis, but subsequent biopsy revealed the diagnosis of sarcoidosis.

![PET/CT and pathology slides of case no. 2. (a, b) Initial PET/CT and chest CT showing para-hilar lymph nodes involvement. (c, d) PET/CT and chest CT at 6 months showing stability of the lymph nodes. Patient subsequently underwent endobronchial biopsy showing non-caseating granulomas consistent with sarcoidosis. (e) Lymph node diffusely replaced by compact non-necrotizing granulomas (4×). (f) Granulomas are formed of clusters of epithelioid histiocytes and have well demarcated margins (10×).](10.1177_2036361318787626-fig1){#fig1-2036361318787626}

Treatment and outcomes {#section9-2036361318787626}
----------------------

All GIST cases were treated with imatinib and two of them were subsequently treated with sunitinib. The patient with unclassified spindled and epithelioid cell sarcoma that coexisted with tenosynovial giant cell tumor was treated with resection and local radiation. The patient with uterine leiomyosarcoma was treated with surgical resection plus multiple lines of chemotherapy including gemcitabine/docetaxel, doxorubicin, ifosfamide, and palliative radiation. Finally, the case of myxofibrosarcoma was given doxorubicin plus cyclophosphamide followed by resection and local radiation.

With a median follow-up period of 29.5 months, three of our sarcoma cases have not shown progression, two patients are alive with current evidence of sarcoma, two patients died due to complications from the primary tumor, and one patient was lost to follow-up. Four out of five patients with GIST are alive on follow-up, two with no evidence of disease and two alive with disease, the remaining case was lost to follow-up. Regarding non-GIST STS, 2 patients are deceased, and one is alive with no evidence of disease.

Statistical analysis {#section10-2036361318787626}
--------------------

The annual incidence of sarcoidosis is estimated at 1--35 cases per 100,000^7^ and the incidence of soft-tissue sarcoma is 3.7 cases per 100,000 in the general US population.^[@bibr1-2036361318787626]^ By December 2016, the catchment area of our hospital was 6.5 million individuals and the population of the state of Florida 20.2 million. Assuming independence, the expected number of patients with both sarcoma and sarcoidosis is 2.6 for the state of Florida and 0.84 for our catchment area in the period of 2007--2016, corresponding to the time interval when our cases were initially seen. Assuming all sarcoma patients in the state of Florida were to be seen at our center, the estimated risk of having sarcoma and sarcoidosis was significantly higher than expected (SIR = 305; 95% CI: 131--556), indicating the probability of coexistence of these two entities is 205% higher than expected. Similarly, the estimated risk of both diseases was even greater if one were to consider our catchment area of five counties in South Florida (SIR = 950; 95% CI: 407--1727), indicating an incidence 850% higher than expected.

Discussion {#section11-2036361318787626}
==========

The objective of this retrospective case series was to determine whether there was evidence of an association between soft-tissue sarcoma and sarcoidosis or if this observation is due to chance alone. Sarcoidosis has been previously associated with a twofold increased risk of development of cancer, most commonly lung, cutaneous, and hematologic malignancies.^[@bibr11-2036361318787626],[@bibr22-2036361318787626]^ Some hypothesize the finding of sarcoidosis following cancer diagnosis may represent an immunologic response to the underlying tumor. This "sarcoid-like reaction" predominantly occurs in patients with Hodgkin disease and, to a lesser extent, in individuals with other hematologic malignancies and solid tumors.^[@bibr23-2036361318787626]^ Our results represent the first series of patients with soft-tissue sarcoma and sarcoidosis and point to a novel, nonrandom, statistically robust association between these two entities. Moreover, our results likely underestimate the association as we are likely missing patients with occult sarcoidosis not detected on routine imaging as well as the fact our center does not see all sarcoma patients in our state nor in our catchment area.

Prior reports in other types of cancer have been inconsistent in terms of prognostic implications. In patients with Hodgkin lymphoma and gastric carcinoma, the presence of sarcoid reactions has been associated with favorable prognosis.^[@bibr22-2036361318787626],[@bibr23-2036361318787626]^ On the contrary, as previously mentioned, a large retrospective cohort of sarcoidosis following the diagnosis of cancer showed that "sarcoid reactions" were associated with recurrence of disease in 53% of cases and secondary malignancies in 67%. The authors concluded that finding sarcoidosis in cancer patient should mandate closer cancer surveillance.^[@bibr12-2036361318787626]^ The cases we presented have mixed outcomes from their sarcoma. Three of the patients have no evidence of disease, two with sarcoidosis discovered after diagnosis of cancer (follow-up 36 and 4 months, respectively) and one with history of sarcoidosis before diagnosis of sarcoma (follow-up of 8.8 years). In three of our cases, the presence of sarcoidosis coexisted with sarcoma progression.

Interestingly, five out of our eight patients have GIST which is significantly higher than expected for the relative incidence of GIST to other STS (1:6). A possible explanation is the role of colony-stimulating factor 1 (CSF-1) in the pathogenesis of both malignancy and sarcoidosis. CSF-1, and its receptor CSF-1R, is overexpressed and drives proliferation of many malignancies and tumor-associated macrophages (TAM) which are involved in tumor progression. In patients with sarcoidosis, CSF-1, CSF-1R, and interleukin (IL)-3 (another ligand of CSF-1R) are increased in bronchoalveolar lavage samples and decreases after treatment with steroids. CSF-1R is a receptor tyrosine kinase (RTK) and shares a significant proportion of amino acid identity with KIT, PGFR, and FLT3. This family of RTKs is an essential component of signaling transduction in cellular growth, differentiation, and motility.^[@bibr24-2036361318787626]^ In the case of GIST, there is also evidence that CSF-1R mutation (D802V) results in alteration at the binding site leading to resistance to imatinib.^[@bibr25-2036361318787626]^ These findings illustrate the possibility of an immune reaction in sarcoma-related sarcoidosis that may be driven by oncogenic tumor pathways. For this reason, additional investigation into the molecular mechanism of sarcoidosis including the possibility of an immune response to occult metastatic sarcoma could provide better understanding of the disease and open new therapeutic approaches.

Clinically, our findings are particularly important as the lung is the most common site of sarcoma metastasis. Thus, not all patients with lung nodules are subjected to a biopsy to confirm metastatic sarcoma. Conversely, the results of this study support the idea that patients with presumed metastatic sarcoma should be considered for a biopsy to exclude other entities such as sarcoidosis. This could be critical as a patient with erroneously presumed metastatic sarcoma may not be treated with curative intent. On the contrary, we agree with previous recommendations stating that the presence of sarcoidosis dictates closer monitoring as it is not always an isolated benign finding. When sarcoidosis is discovered as part of surveillance, biopsy is not enough to secure that sarcoidosis is an isolated process as often not all suspicious sites are sampled. Noninvasive imaging techniques are under investigation to address this problem. Fluoride-18-methyltyrosine (18F-FMT) has been shown to have uptake by malignancy (lymphoma, brain tumors, and experimental tumor models) but not by sarcoidosis. A recent study of 24 patients with sarcoidosis and 17 patients with lung cancer found lung cancer lesions showed uptake of both 18F-FDG and 18F-FMT tracers, while patients with sarcoidosis had uptake of only 18F-FDG. Introduction of such techniques may be very important for better surveillance of cancer patients.^[@bibr26-2036361318787626]^

Conclusion {#section12-2036361318787626}
==========

Although our results should be viewed as exploratory due to the small sample size, this series of eight sarcoma patients with sarcoidosis indicates an intriguing association which may be much more common than previously thought. This association may have impact on identification of patients falsely diagnosed with metastatic disease. Moreover, the association opens the door to additional studies to fully understand the molecular pathogenesis. Our observations highlight the importance of future investigation into sarcoma-related sarcoidosis.
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